This Week’s Small-Cap Healthcare Roundup
Insights - Tekmira Pharmaceuticals (TKMR)Â was the momentum stock of the week as the spread of Ebola continues in Guinea, Liberia and Sierra Leone, and two infected Americans … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Arena Pops then Drops Following Earnings Beat
Insights - Arena Pharmaceuticals (ARNA) reported a surprising earnings beat and profit in its second quarter, with EPS of $0.03, $0.14 better than Wall Street analysts who called for a … Continue Reading
Read now
Into Orexigen, Yet Again
Research - Orexigen Therapeutics (OREX) has again dipped below $5.50, which we find attractive 6 weeks ahead of the September 11 PDUFA decision for NB32 (Contrave, naltrexone/bupropion), … Continue Reading
Read now
KaloBios Moves Ahead with Phase II as Sanofi Kills Collaboration
Insights - KaloBios Pharmaceuticals (KBIO) slid 16% to $1.61 in after hours trading on the news that Sanofi Pasteur, the vaccines division of French pharma giant Sanofi, … Continue Reading
Read now
AcelRx’s Zalviso Met with a CRL
Research - After the bell on Friday evening, AcelRx (ACRX) reported that the FDA has issued a Complete Response Letter (CRL) to the company’s new drug application for Zalviso (sufentanil … Continue Reading
Read nowBiopharma Earnings are Under Way; Our Top Stories this Past Week
Insights - The story of the week was Puma Biotechnology’s (PBYI) unexpected success in the phase 3 ExteNET trial, which sent the stock soaring 200% in after hours trading on Tuesday … Continue Reading
Read now
No One’s Excited about OncoGeneX, Which Makes it Worth a Look
Research - OGXI is a speculative, micro-cap oncology company – now, essentially a call option with multiple shots on goal. $60 million in cash/equivalents provide a backdrop … Continue Reading
Premium